Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis
Purpose: This meta-analysis provides a longitudinal assessment of depression and cognitive impairment induced by taxane-based chemotherapy in women with breast cancer after 6 months of treatment. We highlighted the incidence and prevalence, the cognitive pattern in neuropsychological studies, and th...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.642382/full |
id |
doaj-6484326be758473fbcf0a76d48a68382 |
---|---|
record_format |
Article |
spelling |
doaj-6484326be758473fbcf0a76d48a683822021-04-30T17:13:41ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-04-011110.3389/fonc.2021.642382642382Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-AnalysisEiman Y. Ibrahim0Ilaria Domenicano1Kate Nyhan2Mohamed Elfil3Sarah S. Mougalian4Brenda Cartmel5Barbara E. Ehrlich6Department of Pharmacology, Yale University, New Haven, CT, United StatesDepartment of Biostatistics, Yale School of Public Health Yale University, New Haven, CT, United StatesHarvey Cushing/John Hay Whitney Medical Library and Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT, United StatesDepartment of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, United StatesDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT, United StatesDepartment of Chronic Disease Epidemiology Yale School of Public Health and the Yale Cancer Center, Yale School of Public Health, New Haven, CT, United StatesDepartment of Pharmacology, Yale University, New Haven, CT, United StatesPurpose: This meta-analysis provides a longitudinal assessment of depression and cognitive impairment induced by taxane-based chemotherapy in women with breast cancer after 6 months of treatment. We highlighted the incidence and prevalence, the cognitive pattern in neuropsychological studies, and the relationship between chemotherapy-induced cognitive impairment and different risk factors. We estimated the effect sizes on each cognitive domain and differentiated effect sizes by each method of comparison of effects (i.e., baseline data, or control groups).Methods: The databases MEDLINE and Embase were searched for publications about taxane-related cognitive changes in patients with breast cancer published from 1980 to 2019. Cross-sectional and self-reported outcomes studies were excluded except for the depression item. Included studies were assessed for risk of bias with the Newcastle–Ottawa Scale. We estimated effect sizes for each cognitive domain and differentiated effect sizes by each method of comparison of effects. The review is reported in compliance with the PRISMA Statement; it was registered prospectively in PROSPERO as CRD42020163255.Results: Eleven studies meeting the criteria were analyzed, which resulted in a sample of 1,057 patients with breast cancer who received chemotherapy including 820 patients (77%) who received taxane-based chemotherapy. Attention and concentration, depression, and executive function domains had significant chemotherapy-induced impairment across all comparison types. Statistically significant improvement was found in language and verbal memory when comparing chemotherapy patients' test scores with baseline or matched controls. Taxane-based chemotherapy had a non-significant effect on processing speed, visual memory, visuospatial, and motor function domains.Conclusions: The occurrence of chemotherapy-induced cognitive impairment 6 months or more after the course of treatment in people with breast cancer is frequent in the domains of attention, executive function, and depression. Other domains appear stable or improve with time after treatment cessation.https://www.frontiersin.org/articles/10.3389/fonc.2021.642382/fullchemobraintaxanecognitive impairmentneuropsychologyneurophysiologybreast cancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eiman Y. Ibrahim Ilaria Domenicano Kate Nyhan Mohamed Elfil Sarah S. Mougalian Brenda Cartmel Barbara E. Ehrlich |
spellingShingle |
Eiman Y. Ibrahim Ilaria Domenicano Kate Nyhan Mohamed Elfil Sarah S. Mougalian Brenda Cartmel Barbara E. Ehrlich Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis Frontiers in Oncology chemobrain taxane cognitive impairment neuropsychology neurophysiology breast cancer |
author_facet |
Eiman Y. Ibrahim Ilaria Domenicano Kate Nyhan Mohamed Elfil Sarah S. Mougalian Brenda Cartmel Barbara E. Ehrlich |
author_sort |
Eiman Y. Ibrahim |
title |
Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis |
title_short |
Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis |
title_full |
Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis |
title_fullStr |
Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis |
title_full_unstemmed |
Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis |
title_sort |
cognitive effects and depression associated with taxane-based chemotherapy in breast cancer survivors: a meta-analysis |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-04-01 |
description |
Purpose: This meta-analysis provides a longitudinal assessment of depression and cognitive impairment induced by taxane-based chemotherapy in women with breast cancer after 6 months of treatment. We highlighted the incidence and prevalence, the cognitive pattern in neuropsychological studies, and the relationship between chemotherapy-induced cognitive impairment and different risk factors. We estimated the effect sizes on each cognitive domain and differentiated effect sizes by each method of comparison of effects (i.e., baseline data, or control groups).Methods: The databases MEDLINE and Embase were searched for publications about taxane-related cognitive changes in patients with breast cancer published from 1980 to 2019. Cross-sectional and self-reported outcomes studies were excluded except for the depression item. Included studies were assessed for risk of bias with the Newcastle–Ottawa Scale. We estimated effect sizes for each cognitive domain and differentiated effect sizes by each method of comparison of effects. The review is reported in compliance with the PRISMA Statement; it was registered prospectively in PROSPERO as CRD42020163255.Results: Eleven studies meeting the criteria were analyzed, which resulted in a sample of 1,057 patients with breast cancer who received chemotherapy including 820 patients (77%) who received taxane-based chemotherapy. Attention and concentration, depression, and executive function domains had significant chemotherapy-induced impairment across all comparison types. Statistically significant improvement was found in language and verbal memory when comparing chemotherapy patients' test scores with baseline or matched controls. Taxane-based chemotherapy had a non-significant effect on processing speed, visual memory, visuospatial, and motor function domains.Conclusions: The occurrence of chemotherapy-induced cognitive impairment 6 months or more after the course of treatment in people with breast cancer is frequent in the domains of attention, executive function, and depression. Other domains appear stable or improve with time after treatment cessation. |
topic |
chemobrain taxane cognitive impairment neuropsychology neurophysiology breast cancer |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.642382/full |
work_keys_str_mv |
AT eimanyibrahim cognitiveeffectsanddepressionassociatedwithtaxanebasedchemotherapyinbreastcancersurvivorsametaanalysis AT ilariadomenicano cognitiveeffectsanddepressionassociatedwithtaxanebasedchemotherapyinbreastcancersurvivorsametaanalysis AT katenyhan cognitiveeffectsanddepressionassociatedwithtaxanebasedchemotherapyinbreastcancersurvivorsametaanalysis AT mohamedelfil cognitiveeffectsanddepressionassociatedwithtaxanebasedchemotherapyinbreastcancersurvivorsametaanalysis AT sarahsmougalian cognitiveeffectsanddepressionassociatedwithtaxanebasedchemotherapyinbreastcancersurvivorsametaanalysis AT brendacartmel cognitiveeffectsanddepressionassociatedwithtaxanebasedchemotherapyinbreastcancersurvivorsametaanalysis AT barbaraeehrlich cognitiveeffectsanddepressionassociatedwithtaxanebasedchemotherapyinbreastcancersurvivorsametaanalysis |
_version_ |
1721497740166299648 |